Sanofi is streamlining its operations after its purchase of Genzyme, CEO Christopher Viehbacher said at the annual JPMorgan Chase Healthcare Conference. Genzyme's labs will be maintained and a Sanofi research facility in New Jersey will be closed. "Genzyme's having a big impact on the Sanofi culture," Viehbacher said. Genzyme is good at testing targets early to ensure success, he said, and "that's a skill the industry is going to need to have."

Related Summaries